Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $25.00 target price on the stock.
Separately, Piper Sandler decreased their target price on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 5th.
Check Out Our Latest Stock Report on MIST
Milestone Pharmaceuticals Price Performance
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. As a group, analysts anticipate that Milestone Pharmaceuticals will post -0.79 earnings per share for the current year.
Institutional Trading of Milestone Pharmaceuticals
A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. BML Capital Management LLC raised its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) by 62.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 442,352 shares of the company’s stock after buying an additional 169,852 shares during the quarter. Milestone Pharmaceuticals comprises 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd largest position. BML Capital Management LLC owned approximately 1.32% of Milestone Pharmaceuticals worth $739,000 as of its most recent SEC filing. 86.18% of the stock is owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
- Five stocks we like better than Milestone Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Use the MarketBeat Excel Dividend Calculator
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How Investors Can Find the Best Cheap Dividend Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.